Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Peficitinib likely efficacious and safe

Peficitinib likely efficacious and safe

EULAR 2019
Peficitinib, an orally bioavailable Janus kinase (JAK) inhibitor, showed efficacy as once-daily monotherapy in patients with moderate-to-severe rheumatoid arthritis (RA) in a phase 2b study. It demonstrated significant superiority versus placebo in reducing RA symptoms and in suppressing joint destruction in RA patients who had an inadequate response to methotrexate. Peficitinib also showed satisfactory safety and tolerability. Peficitinib inhibits JAK1, JAK2, JAK3, and tyrosine kinase 2 (Tyk2) enzyme activities. A 52-week Japanese trial conducted by Takeuchi et al. (Keio University, Japan) aimed to evaluate the efficacy and safety of peficitinib–methotrexate combination in patients with RA who had an inadequate response to methotrexate [1,2]. The study was set up as a multicentre, randomised, double-blind, parallel-group, placebo-controlled trial. Eligible patients were adults with RA <10 years (2010 ACR/EULAR criteria) who had signs of active d...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on